OncoPharm

Recapping what I learned at HOPA 2026: -Beyond steroids for irAs -IT chemo beyond methotrexate and cytarabine -Pre-emptive CMV management in patients receiving certain bispecifics -semaglutide-alectinib drug interaction -Safety (n = ~40) of MMR vaccine in patients post-Auto transplant on maintenance daratumumab Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Nivolumab-AVD is finally approved for Hodgkin Lymphoma, and primary G-CSF prophylaxis is recommended (?) in the PI. Also, brief NOLA preview for HOPA attendees. The Big Easy Debate: sazerac or hurricane? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Tazemetostat is withdrawn from the market due to a risk of secondary malignancies. RECITE asks if romiplostim improves platelet counts for patients on oxaliplatin-based regimens with thrombocytopenia. Spoiler - yes it does, but does that make a difference? Check out the Oncology Insights Newsletter: www.kelleycpharmd.com/newsletter-oncopharm

Lots of FDA approval updates to discuss from the past few weeks: -Zongertinib gets approved in 1st line setting for ERBB2 TKD mutated metastatic NSLCLC -Encorafenib approval with cetuximab + FOLFOX -Teclistamab + Daratumumab approved in 2nd line setting for r/r multiple myeloma -Acalabrutinib + venetoclax (but NOT acalabrutinib + venetoclax + obinutuzumab) is approved for CLL Check out the Oncolog...

This week discuss BR.31 trial of adjuvant durvalumab in NSCLC and put it into the context of the positive studies with atezolizumab and pembrolizumab. We also highlight 2 notable presentations at ASCO GU 2026 on perioperative enfortumab vedotin + pembrolizumab in cisplatin-eligible patients with resectable bladder cancer (KEYNOTE-B15) and advjuant pembrolizumab + belzutifan in RCC (LITESPARK-022)...

An exciting new drug, rezatapopt, may be effective in restoring p53 activity in cancers - a possible major therapeutic breakthrough. Can colchicine treat pyrexia from tremetinib & dabrafenib use? This case series says - maybe: https://doi.org/10.1007/s00520-019-4654-2 Check out the Oncology Insights Newsletter: https://www.kelleycpharmd.com/newsletter-oncopharm

The EV-303 trial that led to the FDA approval of perioperative enfortumab vedotin + pembrolizumab in cisplatin-ineligible bladder cancer patients in now published in NEJM. We discuss the results and ponder potential future changes to treating bladder cancer in the future. Urinary diversion surgeries: https://jamanetwork.com/journals/jamaoncology/fullarticle/2842595

We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing). Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)

A brief discussion of the Core Communication Skills* and how to incorporate them into a chemotherapy education session. *Rapport Building *Agenda Setting *Information Management *Active Listening *Addressing Feelings *Common Ground

Reviewing the hot-off-the press publication of PATINA, palbociclib in HER-2 amplified breast cancer along with endocrine therapy and HER-2 targeted antibodies.

We review the recent ASCENT-04/Keynote-D19 publication of sacituzuab govitecan + pembrolizumab for PD-L1 CPS of 10% and above TNBC compared to chemo + pembrolizumab alone. Also, a quick recap of ASCO GI earlier this month with mentions of zanidatamab and zolbetuximab. Finally, a check-in on The Pitt.

This episode is the 2nd chapter in a broader presentation about putting together the puzzle pieces of oncology drug use. This chapter discusses examples of how oncology drug use changes over time. Video & slides available at: https://youtu.be/Kxs0Xg9Ug_c?si=yOwEU1X-7mCPoQl5

A Holiday tradition like few other. Are we keeping, regifting, or returning new oncology drugs approved in 2025?

Are we nearing the end of the Platinum Era in bladder cancer? A press release suggests enfortumab vedotin + pembrolizumab in a perioperative approach is better than the current standard of care: neoadjuvant cisplatin-based chemo followed by surgery. We eagerly await seeing this data. Also, a subcutaneous amivantamab/hyaluronidase formulation is approved, which offers a much lower risk of infusion...

ASH 2025 Highlights: MajesTEC-3: Teclistamab + Daratumumab in relapse refractory Multiple Myeloma Paradigm: HMA + Ven vs. 7+3 or CPX-351 Denosumab safety & dosing in Multiply Myeloma and renal dysfunction Trilaciclib and CDK 4/6 inhibition as protection against TP53-mutated clonal hematopoiesis?

DPYD testing is more complicated than one would think! We talk through the steps to consider when initiating DPYD testing at your site. Resources below: Guide for implementing DPYD testing at your site: https://doi.org/10.1002/cpt.3567 CPIC Dosing Guidline: https://doi.org/10.1002/cpt.911 CPIC DPYD Resources: https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/

We are back with lots of OncoPharm updates: 1. The belantamab mafodotin REMS program details are available....and it's a lot. How will belantamab mafodin-regimens be used with the upcoming MAJESTIC-3 data of teclistamab-daratumumab? 2. The capecitabine label is updated and calls for pre-treatment DPYD testing 3. Daratumumab gets an FDA approval for high-risk smoldering myeloma based on the AQUILA...

Our 3rd and final installment in this Oncology Pharmacy Training Pathways mini-series discusses the PGYNone route. I am joined by Vineetha Thomas and Sheila Pierre to discuss their experiences in becoming oncology pharmacists, forgoing residency training, positions they held earlier in their career, and ultimately becoming thriving oncology pharmacists. This mini-series is supported by the ELO Col...

Our 2nd installment in this Oncology Pharmacy Training Pathways mini-series discusses the PGY1 pharmacy residency route, without a PGY2 oncology residency. I am joined by Kayla Fry and Amber Burgess to discuss their experience to becoming oncology pharmacists. There are some similarities and differences in their paths to their current roles (and one It's-A-Small-World shared connection too!) This...

Our 1st installment in this Oncology Pharmacy Training Pathways mini-series discusses the PGY2 oncology pharmacy residency rout. I am joined by Brooke Adams and Sarah Wheeler to discuss our experience and PGY2 training. We discuss the pros/cons of pursuing a PGY2 oncology residency with the understanding that residency training (or additional residency) training isn't for everyone. This mini-serie...

[Moving Trailer Voice] This Halloween: They always come back.... The latest revival is belantamab mafodotin, FDA approved...again. After being vanquished in DREAMM3, it returned in DREAMM7 and even Daratumumab (in combination with Vd) couldn't overcome this blindingly effective drug (in combination with Vd). This pod reviews belantamab mafodotin's checkered past and wonders what the sequels may ha...

This week's episode recaps some highlights from ESMO 2025: 1. Destiny-Breast05: T-DXd > T-DM1 in persistent HER2+ disease after neoadjuvant chemo + surgery 2. Keynote-905: Neoadjuvant Enfortumab Vedotin + pembro in cisplatin-ineligible bladder cancer 3. POTOMAC: Durvalumab + BCG in non-muscle invasive bladder cancer 4. IMvigor011: ctDNA-guided adjuvant atezolizumab in bladder cancer 5. Dynamic-III...

IL-2, one of the founding fathers of our current immunotherapy landscape, is discussed.

Maintenance therapy with ICIs (atezolizumab or durvalumab) is already established in extensive stage small-cell lung cancer, but lurbinectedin enters the chat with a recent FDA approval. Next up - tarlatamab? IMforte (maintenance lurbinectedin + atezolizumab): https://doi.org/10.1016/S0140-6736(25)01011-6 DeLLphi-303 (phase 1b maintenance tarlatamab + ICI): https://doi.org/10.1016/S1470-2045(25)00...

Our Landmarks of OncoPharm series returns to discuss PARAMOUNT, a landmark study that helped solidify the role of maintenance pemetrexed in NSCLC.